Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.56 |
| ▸ | CES2 | O00748 | 2/20 | 0.51 |
| ▸ | ACP3 | P15309 | 2/20 | 0.47 |
| ▸ | MGLL | Q99685 | 1/20 | 0.46 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | TDO2 | P48775 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | XBP1 | P17861 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1712441 | 0.82 | PNMT (0.56) | PNMTCES2ACP3MGLLMRGPRX1 | |
| SCHEMBL16957413 | 0.81 | PNMT (0.50) | PNMTCES2ACP3MGLLIDO1 | |
| SCHEMBL9814678 | 0.80 | PGK1 (0.41) | TSHRMAPK1LMNATP53 | |
| SCHEMBL27743204 | 0.79 | PNMT (0.61) | PNMTCES2ACP3MGLLIDO1 | |
| SCHEMBL799866 | 0.79 | PNMT (0.53) | PNMTCES2ACP3MGLLMRGPRX1 | |
| SCHEMBL19388859 | 0.79 | PNMT (0.53) | PNMTCES2ACP3MGLLMRGPRX1 | |
| SCHEMBL4135956 | 0.79 | PNMT (0.65) | PNMTCES2ACP3MGLLIDO1 | |
| SCHEMBL13855359 | 0.79 | PNMT (0.47) | PNMTCES2ACP3IDO1TDO2 | |
| SCHEMBL1505949 | 0.79 | PNMT (0.47) | PNMTCES2ACP3MGLLIDO1 | |
| SCHEMBL7626469 | 0.77 | PNMT (0.62) | PNMTCES2ACP3MGLLIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120309842-A1 | PROCESSES FOR THE PREPARATION OF CINACALCET | RANBAXY LABORATORIES LIMITED (IN) | 2012-12-06 | — | — | US | claimed |
| US-20170355997-A1 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING PRURITIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-12-14 | — | — | US | disclosed |
| US-9771592-B2 | Methods and compositions for treating or preventing pruritis | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-09-26 | — | — | US | disclosed |
| EP-2170805-B1 | METHODS OF SYNTHESIZING CINACALCET AND SALTS THEREOF | AMGEN INC (US) | 2016-03-16 | — | — | EP | disclosed |
| EP-2170805-B1 | METHODS OF SYNTHESIZING CINACALCET AND SALTS THEREOF | AMGEN INC (US) | 2016-03-16 | — | — | EP | disclosed |
| US-20140303231-A1 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING PRURITIS | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-10-09 | — | — | US | disclosed |
| US-8759586-B2 | Processes for the preparation of cinacalcet | RANBAXY LABORATORIES LIMITED (IN) | 2014-06-24 | — | — | US | disclosed |
| US-8759586-B2 | Processes for the preparation of cinacalcet | RANBAXY LABORATORIES LIMITED (IN) | 2014-06-24 | — | — | US | disclosed |
| US-20120309842-A1 | PROCESSES FOR THE PREPARATION OF CINACALCET | RANBAXY LABORATORIES LIMITED (IN) | 2012-12-06 | — | — | US | disclosed |
| US-20120309842-A1 | PROCESSES FOR THE PREPARATION OF CINACALCET | RANBAXY LABORATORIES LIMITED (IN) | 2012-12-06 | — | — | US | disclosed |
| US-20090137837-A1 | METHODS OF SYNTHESIZING CINACALCET AND SALTS THEREOF | AMGEN INC. | 2009-05-28 | — | — | US | disclosed |
| US-20090124668-A1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2009-05-14 | — | — | US | disclosed |
| US-7482335-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-27 | — | — | US | disclosed |
| WO-2009002427-A2 | METHODS OF SYNTHESIZING CINACALCET AND SALTS THEREOF | AMGEN INC. (US) | 2008-12-31 | — | — | WO | disclosed |
| US-20080027095-A1 | Use Of 3-Substituted-2-(Diphenylmethy)-1-Azabicyclo[2.2.2]Octanes For Treating Mrg-X1 Receptor Mediated Diseases | MERCK SHARP & DOHME CORP. | 2008-01-31 | — | — | US | disclosed |
| US-20070032526-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CARTER PEROY H | 2007-02-08 | — | — | US | disclosed |
| US-7163937-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-16 | — | — | US | disclosed |
| EP-1656345-A1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Bristol-Myers Squibb Company (US) | 2006-05-17 | — | — | EP | disclosed |
| WO-2005021500-A1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-03-10 | — | — | WO | disclosed |
| US-20050054627-A1 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032526-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CCL11, CCL2, CCR1 | PNMT 4431/4885CES2 3062/4885ACP3 3365/4885 |
| US-20120309842-A1 | PROCESSES FOR THE PREPARATION OF CINACALCET | CA4, SI, CA9 | PNMT 4587/4885CES2 630/4885ACP3 776/4885 |
| US-20170355997-A1 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING PRURITIS | ITCH, CCL11, CPA3 | PNMT 1237/4885CES2 555/4885ACP3 357/4885 |
| US-20080027095-A1 | Use Of 3-Substituted-2-(Diphenylmethy)-1-Azabicyclo[2.2.2]Octanes For Treating Mrg-X1 Receptor Mediated Diseases | MRGPRX1, MRGPRX2, MRGPRX4 | PNMT 1808/4885CES2 3736/4885ACP3 4056/4885 |
| US-20140303231-A1 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING PRURITIS | ITCH, CCL11, CPA3 | PNMT 1237/4885CES2 555/4885ACP3 357/4885 |
| US-20090137837-A1 | METHODS OF SYNTHESIZING CINACALCET AND SALTS THEREOF | ACE, SI, REN | PNMT 4502/4885CES2 233/4885ACP3 362/4885 |
| US-20090124668-A1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCL11, CCL2, CCR1 | PNMT 4431/4885CES2 3062/4885ACP3 3365/4885 |
| US-20050054627-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CCL11, CCL2, CCR1 | PNMT 4431/4885CES2 3062/4885ACP3 3365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.